Skip to content

NMIN supports NanoCanada’s Canadian Nanomedicine Cluster initiative

NMIN is collaborating with its partner organization NanoCanada to build a Canadian Nanomedicine Cluster that will offer a hub for collaboration and partnerships, provide a database of expertise and capabilities, and showcase Canada’s leadership on the global stage. As part of this collaboration, NMIN Executive Director Dr. Diana Royce has… Read More »NMIN supports NanoCanada’s Canadian Nanomedicine Cluster initiative

Lipid nanoparticles in COPD treatment & for light-triggered anticancer drug release: two NMIN-supported papers

The research in Small featured below is from the laboratories of Drs. Dominik Witzigmann (top center) and Pieter Cullis (bottom left) at UBC and Dr. Dirk Trauner (bottom right) at New York University. The lead authors are Nisha Chander (top right) and Dr. Johannes Morstein (top left). NMIN-supported research has… Read More »Lipid nanoparticles in COPD treatment & for light-triggered anticancer drug release: two NMIN-supported papers

Inaugural NMIN Postdoctoral Award in Diagnostics winner announced

The NanoMedicines Innovation Network (NMIN) is pleased to announce the recipient of its inaugural NMIN Postdoctoral Award in Diagnostics: Dr. Yih Yang (Ian) Chen. The awardee was selected by the members of NMIN’s Research Management Committee, based on the applicant’s qualifications, as well as the quality of the proposed research… Read More »Inaugural NMIN Postdoctoral Award in Diagnostics winner announced

NMIN names new Scientific Director & CEO Dr. Christine Allen

The NanoMedicines Innovation Network (NMIN), a national research network funded by the Government of Canada, has appointed Dr. Christine Allen Scientific Director & CEO, effective 1 July 2021. Dr. Allen is Associate Vice-President and Vice-Provost, Strategic Initiatives, and Professor in the Leslie Dan Faculty of Pharmacy, at the University of… Read More »NMIN names new Scientific Director & CEO Dr. Christine Allen

Recognition grows for role of LNPs and Canadian biotech in COVID-19 mRNA-based vaccines

Since news of the Pfizer-BioNTech COVID-19 vaccine first broke in November 2020, growing recognition has been given to the Canadian nanomedicine-based component underlying the vaccine’s effectiveness: the lipid nanoparticle (LNP) delivery system that originated from basic research by NMIN Scientific Director Dr. Pieter Cullis that started over 40 years ago… Read More »Recognition grows for role of LNPs and Canadian biotech in COVID-19 mRNA-based vaccines